Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Tuesday, September 29, 2015
U.S. FDA Grants Priority Review Status to sNDA for Anticancer Agent Halaven as Treatment for Soft Tissue Sarcoma
Eisai Receives Additional Approval in Japan for Vascular Embolization Device DC Bead as Treatment of Hypervascular Tumors and Arteriovenous Malformations
Friday, September 25, 2015
Eisai to Sponsor Lectures at Japan Research Center of Fudan University in China
Monday, September 14, 2015
Eisai to Present Latest Clinical Data on Lenvima (Lenvatinib) and Halaven (Eribulin) at European Cancer Congress
Thursday, September 10, 2015
Drugs for Neglected Diseases initiative and Eisai to Test Drug Candidate for Eumycetoma Patients suffering from virtually no R&D for this neglected disease
Friday, July 31, 2015
Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and Pegph20 in Advanced Breast Cancer
Continuation of "Policy for Protection of The Company's Corporate Value and Common Interests of Shareholders (Shareholder Rights Plan)"
Wednesday, July 29, 2015
Eisai's In-House Developed Novel Anticancer Agent Lenvima Receives Breakthrough Therapy Designation From U.S. Fda for Renal Cell Carcinoma
Friday, June 26, 2015
Eisai to Launch New Fine Granule Formulation of Tachyarrhythmia Treatment Tambocor Suitable for Pediatric Patients in Japan
Monday, June 22, 2015
U.S. FDA Approves Eisai's Antiepileptic Agent Fycompa as Adjunctive Treatment For Primary Generalized Tonic-Clonic Seizures

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: